Serum GFAP, NfL, VEGF and Clinical Progression in Progressive MS

Investigation of the Relationship Between Serum GFAP, NfL, and VEGF Levels and Clinical Progression Markers in Progressive Multiple Sclerosis

Status

Not yet recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT07535242

Enrollment

Registered

2026-04-17

Start date

2026-04-21

Completion date

2026-05-05

Last updated

2026-04-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple Sclerosis

Brief summary

This study aimed to investigate whether the biomarkers GFAP, NfL, and VEGF-recently considered important guides for better understanding the pathophysiology of MS-also serve as indicators of clinical progression in MS.

Interventions

None listed

Study design

Observational model

OTHER

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

ALL

Age

18 Years to 60 Years

Healthy volunteers

Inclusion criteria

* Confirmed diagnosis of MS * Progressive type MS * Voluntary participation * Age between 18-60 years * Cooperative * EDSS score ≥ 5.5

Exclusion criteria

* Presence of another neurological disorder * Change in medication within the last 3 months * Relapse within the last 3 months

Design outcomes

Primary

Measure	Time frame	Description
Expanded Disability Status Scale (EDSS)	Baseline	The Expanded Disability Status Scale (EDSS) is a method of quantifying disability in multiple sclerosis. Scores range from 0 to 10, in 0.5-point increments, where 0 indicates normal neurological status and 10 indicates death due to multiple sclerosis. The scale is based on the assessment of functional systems and ambulation, with higher scores reflecting greater disability.
Standardized Mini-Mental Test	Baseline	The Standardized Mini-Mental Test (MMT/MMSE) score ranges from 0 to 30. Higher scores indicate better cognitive function.
Symbol Digit Modalities Test	Baseline	The Symbol Digit Modalities Test (SDMT) is a neuropsychological test used to assess information processing speed, attention, and visual-motor coordination. Score range: Typically 0 to \~110 (number of correct responses in 90 seconds; exact upper limit depends on performance) Higher scores: Indicate better cognitive processing speed and function
Multiple Sclerosis Impact Scale (MSIS-29)	Baseline	Score range: 29-145 (each item scored 1-5) Higher scores: Indicate greater impact of MS on daily life (worse physical and psychological status)
Glial Fibrillary Acidic Protein (GFAP)	Baseline	This biomarker will be analyzed using the Enzyme-Linked Immunosorbent Assay (ELISA)
Neurofilament Light Chain (NfL)	Baseline	This biomarker will be analyzed using the Enzyme-Linked Immunosorbent Assay (ELISA).
Vascular Endothelial Growth Factor (VEGF)	Baseline	This biomarker will be analyzed using the Enzyme-Linked Immunosorbent Assay (ELISA).

Contacts

CONTACTSeda Nur Kemer

sedakemer@gmail.com+903623121919

Outcome results